The future study design emphasizes the importance of combinatorial approach and plans to eliminate the immunosuppressive tumor burden using Aspirin® to block PGE2 and nivolumab to block PD-1/PD-L1 checkpoint axis. The gene discussed is CD274; the disease is neoplasm.